In April 2018, Sigilon announced a strategic collaboration with Eli Lilly

View Press Release 

We are working with Eli Lilly as partner to develop Afibromer™ technology for the treatment of insulin-dependent diabetes. In the Lilly-Sigilon collaboration, Sigilon will create proprietary products comprised of induced pluripotent stem cells, a type of stem cell derived from adult cells, engineered into differentiated insulin-producing pancreatic beta cells and encapsulated using Sigilon’s Afibromer™ technology. The goal of these products will be to restore insulin production over sustained periods without triggering an immune reaction.

Under the terms of the agreement, Lilly will receive an exclusive worldwide license to Sigilon’s Afibromer™ technology for islet cell encapsulation. Sigilon will be responsible for all development activities and costs related to the collaboration until submission of an investigational new drug application (IND). After an IND is submitted, Lilly will be responsible for all clinical development and commercialization activities and costs related to the collaboration.